These studies showed that anti-HER2 peptide vaccines generate a stronger immune response in HER2 IHC1+/2+ BC, and when used for HER2 IHC3+/FISH+ BC, HER2-block should be maintained. This evidence concerns the gene ERBB2 and breast cancer.